Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics, Inc. (Nasdaq: CARM) is a cutting-edge clinical-stage biopharmaceutical company headquartered in Philadelphia, PA. The company is dedicated to developing transformative immunotherapies for cancer and other serious diseases using its proprietary chimeric antigen receptor macrophage (CAR-M) and monocyte cell engineering platforms.
Carisma is pioneering the use of engineered macrophages and monocytes, which are types of white blood cells essential for immune response. By harnessing these cells, Carisma aims to create innovative treatments for diseases with unmet medical needs. The company's leading product candidates include CT-0508 and CT-0525, both targeting HER2-overexpressing tumors.
CT-0508 is a CAR-M therapy currently in a Phase 1 clinical trial, marking the first time engineered macrophages are being tested in humans. It targets patients with recurrent or metastatic HER2-overexpressing solid tumors who have not responded to standard treatments. CT-0525, on the other hand, is an autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy. Recently cleared by the FDA, it has shown promising preclinical results and is expected to begin Phase 1 trials shortly.
The company's collaboration with Moderna, Inc. to develop in vivo CAR-M therapeutics highlights Carisma's commitment to innovative partnerships. This joint effort aims to leverage Moderna's mRNA and lipid nanoparticle (LNP) technologies to create new cancer treatments.
Carisma has also made significant strides in non-oncology applications. Recently, preclinical data demonstrated the efficacy of engineered macrophages in treating liver fibrosis, indicating potential for broader applications of their technology.
Financially, Carisma is robust, with $94.1 million in cash, cash equivalents, and marketable securities as of September 30, 2023. This financial stability enables the company to sustain its planned operations into the first quarter of 2025.
For more information, please visit www.carismatx.com.
Carisma Therapeutics (Nasdaq: CARM) reported Q2 2024 financial results and business highlights. Key points include:
- Initial data for CT-0525, their lead anti-HER2 product, expected by year-end 2024
- Nomination of a liver fibrosis development candidate expected in Q1 2025
- First in vivo CAR-M candidate targeting Glypican-3 for hepatocellular carcinoma nominated under Moderna collaboration
- Cash position of $40.4 million, plus $2.0 million from Moderna, expected to fund operations into Q3 2025
- Q2 2024 net loss of $11.2 million, compared to $19.9 million in Q2 2023
- R&D expenses decreased to $15.3 million from $18.5 million year-over-year
- G&A expenses slightly decreased to $5.6 million from $6.0 million year-over-year
Carisma Therapeutics (Nasdaq: CARM) has announced an upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. The event will take place in San Diego, California, from November 15 to 19, 2024.
The presentation, titled 'Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models', is scheduled for November 17, 2024, from 8:00 am to 5:00 pm. It falls under the session 'MASLD/MASH - Therapeutics: New Agents' and has been assigned the publication number 3214.
Carisma Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing innovative immunotherapies. The poster will be available on the company's website in the 'Publications' section following the start of the poster session.
Carisma Therapeutics Inc. (Nasdaq: CARM) has expanded its Scientific Advisory Board (SAB) by appointing two renowned key opinion leaders in liver fibrosis, Dr. Scott Friedman and Dr. Ira Tabas. This strategic move aims to bolster Carisma's program in developing innovative treatments for advanced liver disease. Steven Kelly, President and CEO of Carisma, expressed enthusiasm about leveraging the extensive experience and groundbreaking research of these experts to enhance the company's efforts in creating engineered macrophage therapies. The addition of these prominent figures to the SAB is expected to provide valuable insights and expertise as Carisma continues its mission to develop transformative treatments for patients.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the appointment of Marella Thorell and Dr. David Scadden to its Board of Directors, effective June 30, 2024. This decision coincides with the resignation of Regina Hodits and Björn Odlander due to other professional commitments. Carisma's leadership highlighted the vast experience that Thorell and Scadden bring to the company, which is expected to enhance the advancement of its cell therapy platform focused on engineered macrophages. The company expressed gratitude to the outgoing board members for their contributions.
Carisma Therapeutics (Nasdaq: CARM) has announced the nomination of the first in vivo CAR-M development candidate, targeting Glypican-3 (GPC3), under its collaboration with Moderna. This candidate is designed to treat solid tumors, including hepatocellular carcinoma (HCC), the fastest-rising cause of cancer-related death in the U.S.
This nomination triggers a $2 million milestone payment to Carisma and leverages Carisma's expertise in engineering CAR-M with Moderna's mRNA and lipid nanoparticle platform. Pre-clinical data show the candidate can create CAR-M directly in vivo, redirecting myeloid cells to attack cancer cells.
The program advances under the 2022 strategic collaboration agreement between Carisma and Moderna, aiming to discover and commercialize in vivo CAR-M therapeutics. Moderna has also nominated four additional undisclosed oncology research targets under this collaboration.
Carisma Therapeutics (Nasdaq: CARM) announced that the FDA granted Fast Track designation for CT-0525, a gene-modified cellular therapy for HER2-overexpressing solid tumors. This designation aims to expedite the development and review of therapies addressing serious conditions with unmet medical needs. The Phase 1 clinical trial is ongoing, focusing on safety, tolerability, and manufacturing feasibility. Initial data is expected by the end of 2024. The trial targets patients with advanced or metastatic solid tumors unresponsive to standard therapies.
Carisma Therapeutics, a clinical-stage biopharmaceutical company specializing in innovative immunotherapies, has announced its participation in the Stifel 2024 Cell Therapy Forum.
Steven Kelly, President and CEO, will engage in a fireside chat on July 9, 2024, at 9:10 am ET. This session will be available via an audio webcast on the Investor Events section of Carisma's Investor Relations webpage and will remain archived for a period.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced the adjournment of its annual stockholder meeting on June 13, 2024, due to technical difficulties. The meeting will reconvene virtually on June 14, 2024, at 10:00 a.m. Eastern Time. Stockholders can attend online, vote electronically, and submit questions via a virtual audio web conference.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company, announced its participation in the Jefferies Global Healthcare Conference. Steven Kelly, President and CEO, will join a fireside chat on June 6, 2024, at 3:00 pm ET. An audio webcast will be available on the Investor Events section of the company's website and archived for a time.
Carisma Therapeutics (Nasdaq: CARM) has dosed the first patient in its Phase 1 clinical trial of CT-0525, a novel CAR-Monocyte cellular therapy targeting HER2-overexpressing solid tumors. This marks the first human trial for CAR-Monocytes in a solid tumor setting. Initial data is anticipated by year-end 2024. The trial, open-label in design, aims to evaluate the safety, tolerability, and manufacturing feasibility of CT-0525. It will include patients with advanced or metastatic HER2-positive tumors that have not responded to standard therapies. The trial's design will be featured at the ASCO 2024 Annual Meeting.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
What is Carisma Therapeutics' core focus?
What are Carisma Therapeutics' leading products?
What recent achievements has Carisma Therapeutics made?
Who are Carisma Therapeutics' key partners?
Where is Carisma Therapeutics headquartered?
How is Carisma Therapeutics financially positioned?
What is CT-0508?
What is CT-0525?
What types of diseases is Carisma Therapeutics targeting?
How can I get more information about Carisma Therapeutics?
